Iris TumorDiagnostics and screeningHealthy volunteers
What this study is
This is an observational study using OCT angiography to assist with tumor characterization in melanotic and amelanotic iris lesions. OCT angiography data from healthy eyes will be compared to eyes with various types of iris tumors.
Study details
- Sponsor
- Oregon Health and Science University
- Conditions
- Iris Tumor
- Enrolling
- 100 people
- Starts
- 2018-06-20
- Est. completion
- 2027-12
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Acceptedtumor group
You may qualify if
- Eyes with diagnosis of melanotic or amelanotic iris tumors
You can't join if
- Inability to give informed consent
- Inability to maintain stable fixation for OCT imaging
- Inability to commit to required study visits
- Eyes with concurrent retinal diseases, glaucoma, or conditions that in the opinion of the investigators might affect iris circulation
- Mature cataracts if found to limit visual potential to worse than 20/40
healthy control group
You may qualify if
- Eyes without iris defects or lesions
You can't join if
- Inability to give informed consent
- Inability to maintain stable fixation for OCT imaging
- Inability to commit to required study visits
- Eyes with concurrent retinal diseases, glaucoma, or conditions that in the opinion of the investigators might affect iris circulation
- Mature cataracts if found to limit visual potential to worse than 20/40
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
1
Study locations (1)
1 openOregon Health & Science University
Portland, Oregon, United States
- Denzil Romfh, OD · Contact503-494-4351romfhd@ohsu.edu
- Humberto Martinez, COT · Contact503-494-7712martinhu@ohsu.edu
Recruiting
Study team
Sponsor
Oregon Health and Science University
Study ID 6612-IRIS
Principal investigator
David Huang, MD, PhD
Oregon Health and Science University
Have questions? The contacts above can answer them before you apply.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.